ロード中...
Long‐term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
BACKGROUND: Blinatumomab is a CD19 BiTE (bispecific T‐cell engager) immuno‐oncology therapy that mediates the lysis of cells expressing CD19. METHODS: A pooled analysis of long‐term follow‐up data from 2 phase 2 studies that evaluated blinatumomab in heavily pretreated adults with Philadelphia chrom...
保存先:
| 出版年: | Cancer |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7894150/ https://ncbi.nlm.nih.gov/pubmed/33141929 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33298 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|